PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.03), $0.19 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $23 million versus the consensus estimate of $19.76 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.